Results 131 to 140 of about 43,858 (197)

Efficacy of tofacitinib in the treatment of refractory palmoplantar psoriasis (non-pustular): case report and literature review. [PDF]

An Bras Dermatol
Sakiyama PH, Miot LDB, Miot HA.
europepmc   +1 more source

VIM Gene Variant Association to the Co-Occurrence of Livedoid Vasculopathy, Premature Canities, and Early-Onset Cataracts, and Preliminary Efficacy of Tofacitinib: A Case Report. [PDF]

J Inflamm Res
Zhu Z, Qu H.
europepmc   +1 more source

Tofacitinib in older patients with ulcerative colitis: balancing efficacy and safety. [PDF]

Intest Res
Jung YS.
europepmc   +1 more source

Colon-targeted pH-responsive tofacitinib beads improve ulcerative colitis outcomes with lower systemic exposure. [PDF]

Saudi Pharm J
Ibrahim IM, Qadi O, Ahmed OAA, Kamel F, Magadmi R, Alharthi S.   +5 more
europepmc   +1 more source

Successful treatment of refractory primary follicular mucinosis with Tofacitinib. [PDF]

An Bras Dermatol
Li YL, Fang S.
europepmc   +1 more source

Tofacitinib in the treatment of cardiac sarcoidosis: towards steroid-sparing disease management. [PDF]

Open Heart
Frischknecht L, Stüssi-Helbling M, Tian Y, Mallone A, Farokhnia A, Buechel R, Kolios AG, Nilsson J.   +7 more
europepmc   +1 more source

A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis. [PDF]

Crohns Colitis 360
Kumar A, Baxter J, Rimmer P, Noble B, Bower J, Makki MU, Hatta A, Chikhlia A, Cheesbrough J, Disney B, Muir J, Karova M, Butterworth J, Sagar N, Al-Talib I, Nahal J, Ali N, Sagar V, Varyani F, Smith S, Bourne S, Hsu YK, Eltahir A, de Silva S, Harvey P.   +24 more
europepmc   +1 more source

Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study. [PDF]

Rheumatol Ther
Haraoui B, Choquette D, Sciortino C, Galos C, Roy P, Gruben D, Vaillancourt J, Sampalis JS, Khraishi M.   +8 more
europepmc   +1 more source

Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States. [PDF]

Arthritis Res Ther
Magrey M, Gianfrancesco MA, Fallon L, Yndestad A, Vranic I, Wei Y, Ling YL, Gruben D, Curtis JR.   +8 more
europepmc   +1 more source

Tofacitinib combined with fire needle therapy for refractory cutaneous Rosai-Dorfman disease: a first case report and literature review. [PDF]

Front Med (Lausanne)
Zhang Y, Zheng P, Hu B, Chen L.
europepmc   +1 more source